JD-5037

JD-5037 is a potent CB1R antagonist with an IC50 of 1.5 nM.

Product Specifications

CAS Number

[1392116-14-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Cannabinoid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/JD-5037.html

Concentration

10mM

Purity

99.38

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

NC([C@H](C(C)C)/N=C(NS(=O)(C1=CC=C(Cl)C=C1)=O)\N2N=C(C3=CC=C(Cl)C=C3)[C@@H](C4=CC=CC=C4)C2)=O

Molecular Formula

C27H27Cl2N5O3S

Molecular Weight

572.51

Precautions

H302, H315, H319, H335

References & Citations

[1]Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013 Sep 1;23 (17) :4751-60.|[2]Knani I, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Mol Metab. 2016 Oct 22;5 (12) :1187-1199.|[3]Mukhopadhyay B, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology. 2015 May;61 (5) :1615-26.